Corporate Presentation June 2019...PBI-4050 is a potential first - in-class therapy to reduce...

1

Prometic Life Sciences Inc.

Corporate PresentationJune 2019

© Prometic Life Sciences Inc. 2019 2

Safe Harbour

Forward Looking StatementThis presentation contains forward-looking statements about Prometic’s objectives, strategies and businesses that involve risks and uncertainties. Thesestatements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates andassumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect ourbusiness, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic’s ability to develop,manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, thesuccessful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry,uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that couldcause actual events or results to materially differ from our current expectations in the Annual Information Form for the year ended December 31, 2018, underthe heading “Risk Factors”. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update anyforward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicablesecurities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

Copyright noticeThe information contained in this presentation (including names, images, logos and descriptions portraying Prometic's products and/or services) is theproperty of Prometic Life Sciences Inc., of its divisions and / or of its subsidiaries (“Prometic”) and is protected by copyright, patent and trademark law and / orother intellectual property rights. Neither this presentation nor any part may be reproduced or transmitted in any form or by any means, electronic ormechanical, including printing and photocopying, or by any information storage or retrieval system without prior permission in writing from Prometic.

DisclaimerPrometic reserves the right to make improvements, corrections and/or changes to this presentation at any time.


Company Overview

Key Business Attributes

Small MoleculesPBI-4050 & PBI-4547

BioseparationsAffinity Chromatography

PlasmaRyplazim ™

(plasminogen)

CAD75 MM of cash raised April 2019 Operations in Canada, UK, USA

Ken Galbraith appointed CEO

Small Molecule TherapeuticsPBI-4050 and PBI-4547

4


Small Molecule Program Targeting Fibrosis in Liver, Renal and Respiratory Disease

First-in-class, dual-mechanism GPR84 antagonist/GPR40 agonist small

molecules

Two compounds currently in clinical development: PBI-4050 and PBI-4547

Research focused on antifibrotic pathway regulated by two fatty acid

receptors: GPR40 and GPR84

Lead indication using PBI-4050 to treat Alström Syndrome (ALMS)

• PBI-4050 Phase 3 in ALMS to begin in H2-2019• PBI-4050 Phase 2 in ALMS completed successfully with

dramatic impact on fibrosis in multiple organ systems

Multiple additional clinical studies to be underway in 2019 and 2020 to explore potential in disease indications beyond ALMS

• PBI-4050 Phase 2b in IPF to begin Q4-2019• PBI-4050 Phase 2 in NASH to begin Q4-2019• PBI-4547 Phase 1 in healthy volunteers to begin H2-2019


Rich Pipeline of Early and Late Stage Small Molecule Therapeutics

Product Candidates Indications Segment Pre-clin Ph 1 Ph 2 Ph 3 NDA / BLA

PBI-4050

PBI-4050

PBI-4050

PBI-4547

Alström Syndrome

F2-F3 Liver Fibrosis/Steatosis

Idiopathic Pulmonary Fibrosis

TBD

Small molecule

Small molecule

Small molecule

Small molecule


PBI-4050 An Anti-inflammatory And Anti-fibrotic Agent

Evaluated in over 250 subjects, dosed up to 1,200 mg daily, in 8 clinical studies

Reduces fibrosis via regulation of macrophages, fibroblasts/myofibroblasts,

and epithelial cells

3-pentylbenzeneacetic acid sodium salt with a molecular weight of 228.3, derived from a structure-activity study of sodium

decanoate, a salt of the naturally-occurring medium-chain fatty acid,

decanoic acid

Demonstrated across multiple disease models:• chronic kidney disease (CKD); • diabetic kidney disease (DKD);• lung fibrosis, liver fibrosis;• heart fibrosis, Crohn’s disease, scleroderma

and osteoporosis.

Safety and tolerability well-established; most adverse events are mild and discontinuations

from clinical studies are rare

First-in-class, dual-mechanism GPR84 antagonist/GPR40 agonist

Composition of matter patent coverage in major markets until May 2030


Dual-Mechanism GPR84 Antagonist/GPR40 Agonist

GPR84The Good Cop: GPR40

The down regulation of GPR40 promotes fibrosis.

PBI-4050 ‘stimulates’ or up regulates this receptor to promote healing.

The up regulation of GPR84 promotes fibrosis.

PBI-4050 inhibits the up regulation of this receptor to promote healing.

GPR40

PBI-4050

Epithelial cells Macrophages

Myofibroblasts Podocytes

Macrophages

Fibrosis in Kidney, Heart, Liver, Lung, Pancreas, Skin


Peer-Reviewed Publications of PBI-4050 Mechanism of Action

"PBI-4050 reduces stellate cell activation and liver fibrosis throughmodulation of intracellular ATP levels and LKB1-AMPK-mTOR pathway"


Lead Indication: Alström Syndrome (ALMS)

Rare autosomal recessive genetic disorder with 500 to 1,000 ALMSpatients worldwide

Progressive and severefibrosis affecting heart,kidney, lung and liver Childhood onset with

multiple clinical features

Early onset Type 2 diabetes with

severe insulin resistance

Increasing systemic fibrosis develops, often leading to organ failure

ALMS patient lifeexpectancy rarely exceeds

50 years of age


Transforming ALMS Patient Care

No effective or approved treatments for ALMS patients PBI-4050 is a potential first-

in-class therapy to reduce fibrosis in ALMS patients

Phase 2 clinical study of 12 ALMS patients showed a dramatic impact on fibrosis in multiple organ systems

FDA granted both orphan drug designation and rare pediatric disease designation, EMA granted orphan drug status and UK MHRA granted Promising Innovative Medicine (PIM) status for PBI-4050 in ALMS

Phase 3 clinical study expected to begin by H2-2019

Potential to expand clinical program to other rare diseases similar to ALMS


PBI-4050 Liver Fibrosis Reduction in ALMS Patients

FibroScan score reduced or stabilized in 9 out of 10 patients treated for at least 36 weeks

*Richard Steeds et al manuscript in preparation


Cardiac MRI data for Individual Patients: PBI-4050 Reversing Historical Trend (when MRI historical data is available for ≥ 3 years)

Years

MRI Scoreworsening[% annualChange]

0

#1001#1003

#1004

#1005

#1007

#1009

#1014

#1015

Improvement Trend when on PBI-4050 TreatmentFibrosis Worsening Historical Trend

2

4

6

8

10

12

14

16

18

20

1 2 3 4 5 6*Richard Steeds et al manuscript in preparation


Changes In Cardiac T1 Before And After Treatment

*Richard Steeds et al manuscript in preparation


PBI-4050 ALMS Phase 3 Clinical Study Update

Three FDA Type C meetings held in 2018

and 2019

Clinical study protocol to be finalized after final

comments from FDA/EMA, including composite primary endpoints as

agreed with FDA/EMA

European regulatory input ongoing and investigators

recruited in North America and Europe

Enrollment goal of approximately 42 ALMS subjects, 27 adults and

15 pediatric

Working with well-established international ALMS patient advocacy organizations to assist in

conduct of study

Principal Investigator: Dr. Clair Francomano,

University of Indiana


Proposed NASH Phase 2 Clinical Study

Clinical data from treatment of ALMS patients suggests role for

PBI-4050 in treatment of liver fibrosis in NASH patients with

stage F1-3 liver fibrosis

Principal Investigator: Dr. Stephen Harrison,

Pinnacle Clinical Research, San Antonio,

Texas

Protocol follows FDA Guidance for Industry “Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment”

Start Q4-2019 and primary data in 2021


Significant Small Molecule Milestones Expected During 2019-2021

2019

Initiate Phase 3 study of PBI-4050 in ALMS

Initiate Phase 2b study of PBI-4050 in IPF

Initiate Phase 2 study of PBI-4050 in NASH

Commence Phase 1SAD/MAD study of PBI-4547

2020 2021

Initiate Phase 2 study ofPBI-4547 (liver/renal

indication TBD)

Filing of NDA with FDA/EMAfor PBI-4050 in ALMS

Topline data for PBI-4050in IPF and NASH

Topline data forPBI-4050 in ALMS


Prometic Bioseparations

Established 30 years

Portfolio of commercial chromatography adsorbents

ISO9001:2015 accredited (BSI)

cGMP-standard/clean room manufacture

Regulatory support

Custom development and manufacturing services(adsorbents and DSP’s)

Large scale adsorbent manufacture (275 litre batch size – increasing to

1,000L imminently)

18 Prometic adsorbents used in FDA/EMEA licenced products/processes

Applications in columnsup to 2m diameter

Plasma-Derived TherapeuticsRyplazim™ (plasminogen)

19


Ryplazim™ Overview

Rare Pediatric Disease, Orphan Drug and Fast Track designations received from FDA for Ryplazim™

Significant interest from outside parties and out-licensing/divestiture discussions ongoing and active

Proprietary plasma purification technology enables commercial production of

Plasminogen at scale and positions Prometic as sole global supplier of GMP

Plasminogen (“Ryplazim™”)

Re-filing of BLA with FDA for Ryplazim™ for congenital plasminogen

deficiency on track for Q4-2019

Substantial market opportunity


Rich Pipeline of Plasma-Derived Therapeutics

Product Candidates Indications Segment Pre-clin Ph 1 Ph 2 Ph 3 NDA / BLA

Ryplazim™ IV

Ryplazim™ IV

Congenital Deficiency

Therapy in Acute Conditions

Plasma-derived

Plasma-derived

Priority Indications

IVIG

Plasminogen Sc

Primary Immunodeficiency Diseases

Various Wound Healing

Plasma-derived

Plasma-derived

Development stage assets for prioritization and/or monetization


Ryplazim™ Update

Re-filing of BLA with FDA for Ryplazim™ IV for congenital plasminogen deficiency on track for Q4-2019

Additional regulatory filings for Ryplazim™

outside of USA planned for 2020

Rare Pediatric Disease, Orphan Drug and Fast Track designations received from FDA

Out-licensing process ongoing and active


Ryplazim™ IV Publication of Clinical Data in Blood Journal

CorporateHighlights2019 - 2021

24


Investment Summary

Potential for first-in-class therapy for PBI-4050 in ALMS and multiple opportunities for

expansion and growth

Rich, late-stage pipeline with potential best-in-class drugs

for fibrosis in treatment of liver, renal and respiratory

diseases

PBI-4050 and PBI-4547 clinical development plans ready to

execute, with significant expected milestones over next

12-24 months

Exceptional management team and board, with significant support from recognized

institutional investors

Ryplazim™ partnerships and strategic divestiture expected to further strengthen balance

sheet in 2019 and 2020


Management team

Bruce Pritchard, BA, CA, FioDChief Operating Officer - International & Chief Financial Officer

Patrick Sartore, B.Sc., LLB.Chief Operating Officer - North America & Chief Legal Officer & Corporate Secretary

John Moran MD, FRACP, FACPChief Medical Officer

Martin LeclercChief Talent Officer

Kenneth Galbraith BCom, CAChief Executive Officer

Mr. Kenneth Galbraith was appointed Chief Executive Officer in April 2019, having previously served for 3 years on Prometic’sboard of directors. Mr Galbraith has over 30 years’ experience as director, executive and investor in the Life Science sector. He has led many successful cross-border listings for Canadian companies and has a track record of bringing therapies to market, as well as creating value for investors.

Mr. Bruce Pritchard is the Chief Operating Officer – International and Chief Financial Officer of Prometic Life Sciences (PLI)An accountant by training, he has spent over two decades working in the life sciences and pharmaceutical industry. He has more than twelve years’ experience with PLI and has held a number of senior global positions across the organisation.

Mr. Patrick Sartore is the Chief Operating Officer – North America and Chief Legal Officer & Corporate Secretary of Prometic Life Sciences (PLI). A lawyer by training, he has spent over eighteen years working in the life sciences and pharmaceutical industry. He has more than twelve years’ experience with PLI and has held a number of senior global positions across the organization.

Dr. John Moran is the Chief Medical Officer of Prometic Life Sciences (PLI). He has served as Chief Medical Officer of Prometic since March 1, 2014. From 2010 until joining the Corporation, Dr. Moran was Vice President, Clinical Affairs – Home modalities at DaVita Healthcare Partners Inc.

Martin Leclerc is the Chief Talent Officer of Prometic. After working as a consulting actuary for more than 10 years at the beginning of his career, he has since held a number of senior positions in the human resources field within large global corporations. Martin joined Prometic in May 2017.


Board of Directors

Stefan V. Clulow

Chair of the Board, Prometic

Prof. Simon Best

Lead Independent Director, Prometic.

Kenneth Galbraith

CEO, Prometic.

Zachary Newton

Director, Thomvest Asset Management Inc.

Board member, Ecobee Inc.

Gary J. Bridger

Board member, X4 Pharmaceuticals.

Former Executive VP R&D, Xenon Pharmaceuticals Inc.

Neil A. Klompas

Chief Financial Officer. Zymeworks Inc.

Timothy S. Wach

Managing Director & Board Member of Taxand.

Key: Audit, Risk and Finance Committee HR and Corporate Governance Committee


Multiple Opportunities To Further Strengthen Balance Sheet during 2020 and 2021

Financials Small Molecule segment

CorporatePlasma segment

NASDAQ listing in 2019

Ryplazim™ commercialization deal upside if indications beyond Congenital Plasminogen Deficiency licensed

Monetisation of royalty streams from Ryplazim™

Potential for Priority Review Vouchermonetisation: Ryplazim™ (H1/20)

Potential to sell unused tax losses to controlling shareholder

Potential partnering of PBI-4050 and/or PBI-4547

Monetisation of assets outside of PBI-4050 and PBI-4547

Potential for Priority Review Voucher monetisation: Alström Syndrome (Q4/21)

Corporate Presentation June 2019...PBI-4050 is a potential first - in-class therapy to reduce...

Documents

Transcript of Corporate Presentation June 2019...PBI-4050 is a potential first - in-class therapy to reduce...